Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: Simvastatin with SMT: Simvastatin 40 mg once daily orally
Duration: 6 months
Standard Medical Treatment
Control Intervention1: Placebo with SMT: Placebo with Standard Medical Treatment
Sponsors
Institute of Liver and Biliary Sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1) Diagnosed case of Hepato-pulmonary syndrome AaPO2 > 15 mm Hg on standing room air arterial blood gas (ABG). PaO2 2) Child A/B cirrhosis, Child C with CTP score of more than equals to 10 3) Patient with no liver transplant option
Exclusion criteria
Exclusion criteria: 1) Child-C cirrhosis CTP >10 2) Very Severe HPS 3) Acute-on-chronic liver failure 4) Thrombosis of splenoportal axis 5) Hepatocellular carcinoma 6) Renal dysfunction 7) Patients intolerant to beta blockers (history of hypotension or bradycardia) 8) Contraindication for beta-blockers (history of chronic obstructive pulmonary disease, atrioventricular block) 9) Pregnant females 10) Refusal to participate in the study 11) Hepatic Hydrothorax
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Achievement of complete response by the end of 6 monthsTimepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Development of serious adverse effects leading to withdrawal of the drug or death from any causeTimepoint: 2 years;Severity of Liver DiseaseTimepoint: 6 months;Transplant free survivalTimepoint: 3 and 6 months | — |
Countries
India
Contacts
Public ContactDr Shiv Kumar Sarin
Institute of Liver and Biliary Sciences
Outcome results
None listed